- Home
- GXO vs CNTA Comparison
GXO vs CNTA Comparison
Compare GXO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GXO | CNTA |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GXO | CNTA |
|---|---|---|
| Price | $50.32 | $39.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $67.91 | $43.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $13,178,000,000.00 | $15,000,000.00 |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $5.95 | N/A |
| P/E Ratio | $1,687.67 | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $39.92 | $10.95 |
| 52 Week High | $66.85 | $40.26 |
Technical Indicators
Market Signals| Indicator | GXO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 70.14 |
| Support Level | $48.87 | $39.36 |
| Resistance Level | $55.41 | $39.86 |
| Average True Range (ATR) | 1.51 | 0.09 |
| MACD | 0.39 | -0.19 |
| Stochastic Oscillator | 72.47 | 67.19 |
Price Performance
Historical ComparisonAbout GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.